Am Heart J:疑似CAD患者——CAC评分和SPECT心肌灌注显像后心血管药物的改变

2017-06-12 吴刚 环球医学

具有正常的心肌灌注显像(MPI)结果的有症状患者中,冠状动脉钙化(CAC)评分对随后心血管药物使用改变的影响还未确定。2017年4月,发表在《Am Heart J》的一项研究评估了疑似冠状动脉疾病的患者中,CAC评分和正常单光子发射计算机断层显像(SPECT)MPI后,阿司匹林和他汀使用的改变。


具有正常的心肌灌注显像(MPI)结果的有症状患者中,冠状动脉钙化(CAC)评分对随后心血管药物使用改变的影响还未确定。2017年4月,发表在《Am Heart J》的一项研究评估了疑似冠状动脉疾病的患者中,CAC评分和正常单光子发射计算机断层显像(SPECT)MPI后,阿司匹林和他汀使用的改变。

本研究中,1033名稳定的有症状患者入组,这些患者无已知的冠状动脉疾病史,具有正常的SPECT MPI,同时进行CAC评分。所有患者都有影像学的临床指征,主要是非典型胸痛和呼吸困难,并从医院的门诊中转诊过来。试验后药物改变的数据(随后门诊就诊时开始或停用阿司匹林和他汀治疗)都进行了回顾性收集。患者基于他们的CAC评分分为4组。

结果显示,患者平均61±11岁,39%为男性。基线时,35%的患者使用阿司匹林,39%使用他汀。CAC评分为0、1~99、100~399和≥400的患者中,分别有1%、4%、9%和9%的患者开始阿司匹林,0%、7%、18%和24%的患者开始他汀(P<0.001)。相应CAC评分组中,19%、11%、7%和1%的患者停用阿司匹林,8%、6%、2%和0%的患者停用他汀(P<0.001)。校正了风险因素和基线药物使用的差异后,CAC评分的增加与试验后阿司匹林(CAC评分为1~99、100~399和≥400的比值比分别为4.6、11.2和27.1;P<0.001)和他汀使用(CAC评分为1~99、100~399和≥400的比值比分别为4.4、19.4和60.9;P<0.001)独立相关。

结果表明,正常SPECT MPI患者中,较高的CAC评分与阿司匹林和他汀初始治疗相关。CAC评分较低的患者中,更可能停用心脏保护药物。CAC评分与试验后他汀和阿司匹林的使用独立相关

原始出处:

Engbers EM, Timmer JR, Mouden M, et al. Changes in cardiovascular medication after coronary artery calcium scanning and normal single photon emission computed tomography myocardial perfusion imaging in symptomatic patients. Am Heart J. 2017 Apr;186:56-62. doi: 10.1016/j.ahj.2017.01.009. Epub 2017 Jan 19.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1726471, encodeId=20441e2647111, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Apr 07 22:49:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642506, encodeId=cd261642506e5, content=<a href='/topic/show?id=8210512940e' target=_blank style='color:#2F92EE;'>#心肌灌注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51294, encryptionId=8210512940e, topicName=心肌灌注)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754b22951372, createdName=12498e5fm19(暂无昵称), createdTime=Thu Nov 09 21:49:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646034, encodeId=b4241646034d3, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Tue Nov 28 03:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356325, encodeId=84b113563253d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541641, encodeId=f40c154164121, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562559, encodeId=8d851562559a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2018-04-07 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1726471, encodeId=20441e2647111, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Apr 07 22:49:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642506, encodeId=cd261642506e5, content=<a href='/topic/show?id=8210512940e' target=_blank style='color:#2F92EE;'>#心肌灌注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51294, encryptionId=8210512940e, topicName=心肌灌注)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754b22951372, createdName=12498e5fm19(暂无昵称), createdTime=Thu Nov 09 21:49:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646034, encodeId=b4241646034d3, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Tue Nov 28 03:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356325, encodeId=84b113563253d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541641, encodeId=f40c154164121, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562559, encodeId=8d851562559a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1726471, encodeId=20441e2647111, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Apr 07 22:49:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642506, encodeId=cd261642506e5, content=<a href='/topic/show?id=8210512940e' target=_blank style='color:#2F92EE;'>#心肌灌注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51294, encryptionId=8210512940e, topicName=心肌灌注)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754b22951372, createdName=12498e5fm19(暂无昵称), createdTime=Thu Nov 09 21:49:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646034, encodeId=b4241646034d3, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Tue Nov 28 03:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356325, encodeId=84b113563253d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541641, encodeId=f40c154164121, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562559, encodeId=8d851562559a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1726471, encodeId=20441e2647111, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Apr 07 22:49:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642506, encodeId=cd261642506e5, content=<a href='/topic/show?id=8210512940e' target=_blank style='color:#2F92EE;'>#心肌灌注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51294, encryptionId=8210512940e, topicName=心肌灌注)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754b22951372, createdName=12498e5fm19(暂无昵称), createdTime=Thu Nov 09 21:49:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646034, encodeId=b4241646034d3, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Tue Nov 28 03:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356325, encodeId=84b113563253d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541641, encodeId=f40c154164121, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562559, encodeId=8d851562559a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-14 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1726471, encodeId=20441e2647111, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Apr 07 22:49:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642506, encodeId=cd261642506e5, content=<a href='/topic/show?id=8210512940e' target=_blank style='color:#2F92EE;'>#心肌灌注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51294, encryptionId=8210512940e, topicName=心肌灌注)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754b22951372, createdName=12498e5fm19(暂无昵称), createdTime=Thu Nov 09 21:49:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646034, encodeId=b4241646034d3, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Tue Nov 28 03:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356325, encodeId=84b113563253d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541641, encodeId=f40c154164121, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562559, encodeId=8d851562559a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1726471, encodeId=20441e2647111, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Apr 07 22:49:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642506, encodeId=cd261642506e5, content=<a href='/topic/show?id=8210512940e' target=_blank style='color:#2F92EE;'>#心肌灌注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51294, encryptionId=8210512940e, topicName=心肌灌注)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754b22951372, createdName=12498e5fm19(暂无昵称), createdTime=Thu Nov 09 21:49:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646034, encodeId=b4241646034d3, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Tue Nov 28 03:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356325, encodeId=84b113563253d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541641, encodeId=f40c154164121, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562559, encodeId=8d851562559a2, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jun 14 07:49:00 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-14 slcumt

相关资讯

盘点:近期冠状动脉疾病重大研究进展一览

我国冠心病发病呈逐年增加态势,而经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)是治疗冠心病的主要措施。近20年来,冠状动脉血流储备分数(fractional flow reserve,FFR)逐渐成为公认的有创病变功能学评价指标,以FFR指导的治疗策略被证实安全、经济,并能改善患者的预后。本文梅斯医学小编就近期冠状动脉疾病重大研究进展汇总,

2016ESC专家共识:冠状动脉疾病和/或房颤患者出血后抗栓治疗管理发布

出血是冠状动脉疾病患者管理过程中常见的并发症,尤其是在急性冠脉综合征或接受PCI治疗和房颤患者中。本文主要针对冠状动脉疾病和/或房颤患者出血后抗栓治疗的管理提供了一个欧洲专家共识,包括停用哪些药物,开始应用哪些药物以及应用的时机。全文下载:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积分下载) 

Am J Cardiol: 外周动脉疾病合并冠状动脉疾病的患者,预后不良

目的:指南推荐药物治疗(GDMT)对有无冠状动脉疾病(CAD)外周动脉疾病(PAD)长期临床预后的影响。方法:从2006到2013,共有879跛行或严重肢体缺血(CLI)的患者在多学科的血管中心进行血管内介入诊断或治疗。在造影时评估是否应用GDMT,随访5年确定主要不良心脑血管事件(MACCE)和全因死亡率。应用Cox比例风险模型调整有无CAD患者的基线差异。结果:对阿司匹林、血管紧张素转换酶抑制

Nat Genet:15个全新致病风险位点揭示冠状动脉疾病形成机制

实验数据集包括了88,192个冠状动脉疾病患者和162,544个对照。研究在15个基因组区间上,发现了25个未被报道的与CAD相关的SNP位点(P < 5 × 10−8, 固定效应模型元分析)。和这些区域相关的细胞类型特异的基因表达和血浆蛋白水平清晰的阐明了潜在的疾病作用机制。

JAHA:有症状糖尿病患者但无阻塞性冠状动脉疾病患者雷诺拉嗪疗效如何?

由此可见,在有症状的糖尿病但无阻塞性冠状动脉疾病的患者中,雷诺拉嗪并没有改变运动刺激的心肌血流量或CFR,但可以适度改善舒张功能。基础CFR受损更严重的患者可能从雷诺拉嗪的治疗中获得更多的益处。

SCI REP: 全新鉴定的15个关于冠状动脉硬化遗传的风险因子

最近,研究人员利用161例遗传突变,通过对独立的遗传变量进行meta分析发现:71个基因突变具有全基因水平的显着性,其中有15个是新的位点。